Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas

BACKGROUND. Src, EphA2, and platelet-derived growth factor receptors α and β are dysregulated in pancreatic ductal adenocarcinoma (PDAC). Dasatinib is an oral multitarget tyrosine kinase inhibitor that targets BCR-ABL, c-Src, c-KIT, platelet-derived growth factor receptor β, and EphA2. We conducted...

詳細記述

保存先:
書誌詳細
主要な著者: Chee, Cheng Ean, Krishnamurthi, Smitha, Nock, Charles J., Meropol, Neal J., Gibbons, Joseph, Fu, PingFu, Bokar, Joseph, Teston, Lois, O'Brien, Timothy, Gudena, Vinay, Reese, Amy, Bergman, Mark, Saltzman, Joel, Wright, John J., Dowlati, Afshin, Brell, Joanna
フォーマット: Artigo
言語:Inglês
出版事項: AlphaMed Press 2013
主題:
Clinical Trial Results
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3805150/
https://ncbi.nlm.nih.gov/pubmed/24072218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0255
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料